View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
WEDNESDAY, Aug. 24 (HealthDay News) -- Botox (onabotulinumtoxinA) has been approved by the U.S. Food and Drug Administration to treat urinary incontinence in people with neurological conditions such as spinal cord injury and multiple sclerosis.
Some people with these conditions have uncontrolled bladder contractions, which leads to inability to retain urine. Common treatments include medication or a catheter. The use of Botox involves injecting the drug into the bladder, relaxing the bladder. The drug's effects last for about nine months, the FDA said.
Botox was evaluated for this use in clinical studies involving 691 people. The most common adverse reactions included urinary tract infection and urinary retention. Botox also is FDA-approved for reducing facial frown lines, and treating chronic migraine, certain forms of muscle stiffness, severe underarm sweating and abnormal twitches of the eyelid.
The drug is marketed by Irvine, Calif.-based Allergan Inc.
To learn more about incontinence, visit the U.S. National Library of Medicine.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top